128 related articles for article (PubMed ID: 2261378)
1. Treatment of metastatic renal cell cancer patients with recombinant subcutaneous human interleukin-2 and interferon-alpha.
Atzpodien J; Körfer A; Palmer PA; Franks CR; Poliwoda H; Kirchner H
Ann Oncol; 1990 Sep; 1(5):377-8. PubMed ID: 2261378
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal cell cancer: the German outpatient experience.
Kirchner H; Körfer A; Palmer PA; Evers P; De Riese W; Knüver-Hopf J; Hadam M; Goldman U; Franks CR; Poliwoda H
Mol Biother; 1990 Sep; 2(3):145-54. PubMed ID: 2222898
[TBL] [Abstract][Full Text] [Related]
3. alpha-Interferon and interleukin-2 in renal cell carcinoma: studies in nonhospitalized patients.
Atzpodien J; Poliwoda H; Kirchner H
Semin Oncol; 1991 Oct; 18(5 Suppl 7):108-12. PubMed ID: 1948123
[TBL] [Abstract][Full Text] [Related]
4. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.
Atzpodien J; Lopez Hänninen E; Kirchner H; Bodenstein H; Pfreundschuh M; Rebmann U; Metzner B; Illiger HJ; Jakse G; Niesel T
J Clin Oncol; 1995 Feb; 13(2):497-501. PubMed ID: 7844611
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients.
Lopez Hänninen E; Kirchner H; Atzpodien J
J Urol; 1996 Jan; 155(1):19-25. PubMed ID: 7490829
[TBL] [Abstract][Full Text] [Related]
6. Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid.
Atzpodien J; Kirchner H; Duensing S; Lopez Hänninen E; Franzke A; Buer J; Probst M; Anton P; Poliwoda H
World J Urol; 1995; 13(3):174-7. PubMed ID: 7550391
[TBL] [Abstract][Full Text] [Related]
7. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
8. Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies.
Atzpodien J; Körfer A; Franks CR; Poliwoda H; Kirchner H
Lancet; 1990 Jun; 335(8704):1509-12. PubMed ID: 1972442
[TBL] [Abstract][Full Text] [Related]
9. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous recombinant interleukin-2 and alpha-interferon in patients with advanced renal cell carcinoma: results of a multicenter Phase II Study.
Atzpodien J; Kirchner H; de Mulder P; Bodenstein H; Oliver T; Palmer PA; Franks CR; Poliwoda H
Cancer Biother; 1993; 8(4):289-300. PubMed ID: 7804370
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of very low doses of immunotherapy in advanced renal cell cancer.
Buzio C; De Palma G; Passalacqua R; Potenzoni D; Ferrozzi F; Cattabiani MA; Manenti L; Borghetti A
Br J Cancer; 1997; 76(4):541-4. PubMed ID: 9275034
[TBL] [Abstract][Full Text] [Related]
12. An outpatient phase II study of subcutaneous interleukin-2 and interferon-alpha-2b in combination with intravenous vinblastine in metastatic renal cell cancer.
Pectasides D; Varthalitis J; Kostopoulou M; Mylonakis A; Triantaphyllis D; Papadopoulou M; Dimitriadis M; Athanassiou A
Oncology; 1998; 55(1):10-5. PubMed ID: 9428369
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-2 in combination with interferon-alpha in disseminated malignant melanoma and advanced renal cell carcinoma. A phase I/II study.
Bergmann L; Weidmann E; Mitrou PS; Runne U; Keilholz U; Bartsch HH; Franks CR
Onkologie; 1990 Apr; 13(2):137-40. PubMed ID: 2197585
[TBL] [Abstract][Full Text] [Related]
14. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
Ryan CW; Vogelzang NJ; Dumas MC; Kuzel T; Stadler WM
Cancer; 2000 Mar; 88(6):1317-24. PubMed ID: 10717612
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.
Ravaud A; Négrier S; Cany L; Merrouche Y; Le Guillou M; Blay JY; Clavel M; Gaston R; Oskam R; Philip T
Br J Cancer; 1994 Jun; 69(6):1111-4. PubMed ID: 8198979
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma.
Mittelman A; Huberman M; Puccio C; Fallon B; Tessitore J; Savona S; Eyre R; Gafney E; Wick M; Skelos A
Cancer; 1990 Aug; 66(4):664-9. PubMed ID: 2386896
[TBL] [Abstract][Full Text] [Related]
17. [Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma].
Atzpodien J; Kirchner H; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():38-43. PubMed ID: 8692118
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-2 and interferon-alpha-2a outpatient therapy for metastatic renal cell carcinoma.
Lipton A; Harvey H; Givant E; Hopper K; Lawler J; Matthews Y; Hirsh M; Zeffren J
J Immunother Emphasis Tumor Immunol; 1993 Feb; 13(2):122-9. PubMed ID: 8318497
[TBL] [Abstract][Full Text] [Related]
19. [Combination therapy with recombinant interferon alpha-21 (rIFN alpha 2a) and recombinant interleukin 2 (rIL-2) in metastatic renal cell cancer].
Jurincic-Winkler C; Horlbeck R; Klippel KF
Wien Klin Wochenschr; 1993; 105(10):271-6. PubMed ID: 8517056
[TBL] [Abstract][Full Text] [Related]
20. A randomized study of low-dose interleukin-2 subcutaneous immunotherapy versus interleukin-2 plus interferon-alpha as first line therapy for metastatic renal cell carcinoma.
Lissoni P; Barni S; Ardizzoia A; Andres M; Scardino E; Cardellini P; Della Bitta R; Tancini G
Tumori; 1993 Dec; 79(6):397-400. PubMed ID: 8171738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
